News / Press Release

Are There Other Ways to Get Investigational Drugs?

February 18, 2017

Although the most common way for patients to get access to an investigational new drug is through a clinical trial, there are other avenues that physicians and patients can pursue.

Expanded Access

Certain investigational new drugs have expanded access protocols. These protocols typically apply to investigational drugs that have been studied extensively and are just waiting on FDA approval for marketing. The FDA process can be slow at times, and expanded access allows a greater number of patients to try the treatment. These treatments normally demonstrate success against certain types of cancers, meaning the evidence is there.

It is up to the investigational new drug application sponsor to apply and make their products available through expanded access. In general, the FDA only approves such an application when there is no other treatment already on the market that has demonstrated similar efficacy.

Special Exemption or Compassionate Exemption

Special exemption, or compassionate exemption, can apply to patients who do not otherwise meet the participation criteria for a clinical trial for an investigational new drug. To qualify for this, a patient’s physician must get in touch with the investigational drug’s sponsor company to provide the medical background and treatment history of the patient. Cases are considered on an individual basis, and the FDA must also approve the application.

In most cases, the sponsor company and FDA must jointly determine that the patient will either experience significantly prolonged survival prospects and an improved quality of life prior to granting compassionate exemption.

When determining whether or not a patient is a good candidate for investigational new drugs, the following questions should be considered:

  1. Is the patient a good candidate for a clinical trial?
  2. Has the patient been subjected to the traditional gamut of medications and therapies for their condition?
  3. Is the active agent in the investigational new drug application related to the disease in question?
  4. What are the risks of exposing the patient to investigational new drugs?
  5. Is there sufficient reason to believe that the patient would benefit from the investigational drug in question?

Unfortunately, even if the patient is an appropriate candidate for compassionate exemption on paper, the request can be denied if the drug is either in short supply or high demand.

For patients, families and physicians who want more information about investigational new drugs, the National Cancer Institute (NCI) maintains a database — the PDQ database — to track the status of ongoing studies. NCI's Cancer Trials website, along with information specialists at NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237), are also available to provide further information.

At TD2, we specialize in getting the best and most innovative oncology treatments to patients in need. Contact us for more information today.

About Translational Drug Development (TD2)

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

About TD2

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

Contact
Tara Franks
602-358-8322
Get free tips, tools and resources by subscribing to the TD2 Newsletter: